Pediatrix Medical Group, Inc. $MD Shares Acquired by Panagora Asset Management Inc.

Key Points

• Panagora Asset Management Inc. increased its stake in Pediatrix Medical Group by 17.7%, acquiring an additional 53,625 shares, bringing its total ownership to 356,982 shares valued at approximately $5.17 million.
• Several other investors also boosted their holdings in Pediatrix, with GAMMA Investing LLC leading with an increase of 219.5% in the first quarter.
• Pediatrix Medical Group reported a quarterly earnings per share of $0.53, exceeding analysts' expectations, and a revenue of $468.84 million, despite a 7.1% decrease compared to the previous year.

Panagora Asset Management Inc. boosted its stake in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 17.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 356,982 shares of the company's stock after acquiring an additional 53,625 shares during the period. Panagora Asset Management Inc. owned 0.42% of Pediatrix Medical Group worth $5,173,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its position in shares of Pediatrix Medical Group by 219.5% in the 1st quarter. GAMMA Investing LLC now owns 2,569 shares of the company's stock worth $37,000 after purchasing an additional 1,765 shares during the last quarter. AlphaQuest LLC increased its holdings in Pediatrix Medical Group by 16.0% in the first quarter. AlphaQuest LLC now owns 5,877 shares of the company's stock valued at $85,000 after buying an additional 811 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Pediatrix Medical Group by 218.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,445 shares of the company's stock valued at $98,000 after buying an additional 5,104 shares in the last quarter. Squarepoint Ops LLC bought a new position in Pediatrix Medical Group during the 4th quarter worth approximately $132,000. Finally, Sherbrooke Park Advisers LLC bought a new position in Pediatrix Medical Group during the 4th quarter worth approximately $136,000. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock traded up $0.05 during midday trading on Friday, reaching $17.06. 1,045,640 shares of the stock traded hands, compared to its average volume of 788,504. Pediatrix Medical Group, Inc. has a fifty-two week low of $10.06 and a fifty-two week high of $17.67. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 13.22 and a beta of 1.29. The firm has a fifty day moving average price of $14.46 and a two-hundred day moving average price of $14.11.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $0.11. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The company had revenue of $468.84 million for the quarter, compared to analysts' expectations of $464.37 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The business's revenue for the quarter was down 7.1% compared to the same quarter last year. On average, equities research analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

MD has been the topic of several research reports. Zacks Research raised Pediatrix Medical Group to a "strong-buy" rating in a research report on Monday, August 11th. Leerink Partners boosted their target price on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the company a "market perform" rating in a research note on Friday. Finally, UBS Group raised their price target on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $16.79.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.